hESC - Derived Therapies (GRNOPC1)
Geron is planning a Phase I multi-center trial that is designed to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) grade A subacute thoracic spinal cord injuries.
 
Patients who will be eligible for the Phase I trial must have documented evidence of functionally complete spinal cord injury with a neurological level of T3 to T10 spinal segments and agree to have GRNOPC1 injected into the lesion sites between seven and 14 days after injury.
 
Although the primary endpoint of the trial will be safety, the protocol will include secondary endpoints to assess efficacy, such as improved neuromuscular control or sensation in the trunk or lower extremities. Once safety in this patient population has been established and the FDA reviews clinical data in conjunction with additional data from ongoing animal studies, Geron plans to seek FDA approval to extend the study to increase the dose of GRNOPC1, enroll subjects with complete cervical injuries and expand the trial to include patients with severe incomplete (ASIA grade B or C) injuries to enable access to the therapy for as broad a population of severe spinal cord-injured patients as is medically appropriate.
 
Currently there are no sites enrolling patients for this study. The Investigational New Drug application (IND) has been placed on clinical hold by the FDA pending the agency's review of new nonclinical animal study data submitted by the company.
 
We do not maintain a mailing list for distribution of information. If you would like to join our email distribution list for press releases, which will inform you about significant company developments, please send your name and email address to Geron at info@geron.com.